JP2014517282A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517282A5
JP2014517282A5 JP2014510754A JP2014510754A JP2014517282A5 JP 2014517282 A5 JP2014517282 A5 JP 2014517282A5 JP 2014510754 A JP2014510754 A JP 2014510754A JP 2014510754 A JP2014510754 A JP 2014510754A JP 2014517282 A5 JP2014517282 A5 JP 2014517282A5
Authority
JP
Japan
Prior art keywords
bladder cancer
subject
prognosis
sample
sample value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014510754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517282A (ja
Filing date
Publication date
Priority claimed from EP11166558A external-priority patent/EP2524928A1/en
Application filed filed Critical
Publication of JP2014517282A publication Critical patent/JP2014517282A/ja
Publication of JP2014517282A5 publication Critical patent/JP2014517282A5/ja
Pending legal-status Critical Current

Links

JP2014510754A 2011-05-18 2012-05-11 膀胱癌におけるｒｂｍ３ Pending JP2014517282A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161487341P 2011-05-18 2011-05-18
EP11166558A EP2524928A1 (en) 2011-05-18 2011-05-18 RBM3 in bladder cancer
EP11166558.4 2011-05-18
US61/487,341 2011-05-18
PCT/EP2012/058826 WO2012156330A1 (en) 2011-05-18 2012-05-11 Rbm3 in bladder cancer

Publications (2)

Publication Number Publication Date
JP2014517282A JP2014517282A (ja) 2014-07-17
JP2014517282A5 true JP2014517282A5 (enExample) 2015-06-25

Family

ID=44358146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014510754A Pending JP2014517282A (ja) 2011-05-18 2012-05-11 膀胱癌におけるｒｂｍ３

Country Status (6)

Country Link
US (4) US20120040338A1 (enExample)
EP (2) EP2524928A1 (enExample)
JP (1) JP2014517282A (enExample)
AU (1) AU2012257798A1 (enExample)
CA (1) CA2834653A1 (enExample)
WO (1) WO2012156330A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
EP2746768A1 (en) * 2012-12-20 2014-06-25 Atlas Antibodies AB Podxl in bladder cancer
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
CN110195109A (zh) * 2019-07-03 2019-09-03 北京太东生物科技有限公司 Rbm46作为睾丸肿瘤标志物的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20090007281A1 (en) 2006-01-13 2009-01-01 Battelle Memorial Institute Animal Model for Assessing Copd-Related Diseases
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
EP2090890A1 (en) 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
CN105224827B (zh) * 2008-07-01 2019-12-24 小利兰·斯坦福大学托管委员会 用于发展ivf治疗协议的分析数据的计算机系统和存储介质
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis

Similar Documents

Publication Publication Date Title
Straver et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy
Yap et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography
Todenhöfer et al. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients
Shin et al. Diagnostic value of circulating extracellular miR-134, miR-185, and miR-22 levels in lung adenocarcinoma-associated malignant pleural effusion
Elsawaf et al. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour
Uhlig et al. Contrast enhancement on cone-beam breast-CT for discrimination of breast cancer immunohistochemical subtypes
Köhler et al. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
Sakamoto et al. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy
JP2014517282A5 (enExample)
Kan et al. The prognosis of subsequent surgical treatment in patients with sarcomatoid carcinoma in the liver: a retrospective study
De-Colle et al. Ex vivo γH2AX radiation sensitivity assay in prostate cancer: inter-patient and intra-patient heterogeneity
Senetta et al. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study
Pannier et al. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer
Kim et al. The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer
Salama et al. FOXP3+ cell density in lymphoid follicles from histologically normal mucosa is a strong prognostic factor in early stage colon cancer
Park et al. Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy
Ademuyiwa et al. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer
Okamoto et al. Risk factors for complications following lateral pelvic lymph node dissection for rectal cancer
Keruakous et al. The impact of isolated tumor cells on loco-regional recurrence in breast cancer patients treated with breast-conserving treatment or mastectomy without post-mastectomy radiation therapy
Nadoshan et al. Prognostic value of lymph node ratios in node positive rectal cancer treated with preoperative chemoradiation
Sharir et al. Lymph node assessment and lymphadenectomy in bladder cancer
Kucuk et al. Significance of TNM staging, demographic and histologic features in predicting the prognosis of renal cell carcinoma
Nowaczyk et al. Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas
JP2016508219A5 (enExample)
Eminaga et al. Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies